Read more
In recent decades, there has been a substantial increase fungal infection (IFI), posing a significant threat to human health. Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus are the predominant pathogens responsible for the majority of IFIs in clinical settings. Despite advances in antifungal therapy, IFIs remain a major cause of morbidity and mortality, especially in immunocompromised and HIV-infected patients. The primary therapeutic families for fungal infections include polyenes, fluoropyrimidines, azoles, allylamines, and echinocandins. However, these antifungal drugs face challenges such as low water solubility, toxicity, narrow-spectrum activity, low bioavailability and, above all, the emergence of fungal drug resistance. To address the urgent medical need for improved antifungal agents, this book explores the application of Computer-Aided Drug Design (CADD) methods.
About the author
Soukaina Bouamrane holds a PhD in Chemistry from the Laboratory of Molecular Chemistry and Natural Substances at the Faculty of Sciences, Moulay Ismail University, Meknes, Morocco. She specializes in computer-aided drug design. She has published numerous research articles in various reputable national and international journals.
